GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000915019 | Prostate | Tumor | purine ribonucleotide metabolic process | 109/3246 | 368/18723 | 3.30e-09 | 1.36e-07 | 109 |
GO:000925918 | Prostate | Tumor | ribonucleotide metabolic process | 110/3246 | 385/18723 | 2.45e-08 | 8.29e-07 | 110 |
GO:000616319 | Prostate | Tumor | purine nucleotide metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:001969318 | Prostate | Tumor | ribose phosphate metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:007252119 | Prostate | Tumor | purine-containing compound metabolic process | 115/3246 | 416/18723 | 8.47e-08 | 2.31e-06 | 115 |
GO:000915218 | Prostate | Tumor | purine ribonucleotide biosynthetic process | 53/3246 | 169/18723 | 5.62e-06 | 8.63e-05 | 53 |
GO:000926016 | Prostate | Tumor | ribonucleotide biosynthetic process | 54/3246 | 182/18723 | 2.71e-05 | 3.29e-04 | 54 |
GO:000911718 | Prostate | Tumor | nucleotide metabolic process | 120/3246 | 489/18723 | 2.81e-05 | 3.41e-04 | 120 |
GO:000675317 | Prostate | Tumor | nucleoside phosphate metabolic process | 121/3246 | 497/18723 | 3.81e-05 | 4.41e-04 | 121 |
GO:004639016 | Prostate | Tumor | ribose phosphate biosynthetic process | 55/3246 | 190/18723 | 4.89e-05 | 5.42e-04 | 55 |
GO:007252215 | Prostate | Tumor | purine-containing compound biosynthetic process | 55/3246 | 200/18723 | 2.16e-04 | 1.86e-03 | 55 |
GO:000616415 | Prostate | Tumor | purine nucleotide biosynthetic process | 53/3246 | 191/18723 | 2.18e-04 | 1.87e-03 | 53 |
GO:000916514 | Prostate | Tumor | nucleotide biosynthetic process | 61/3246 | 254/18723 | 4.03e-03 | 2.04e-02 | 61 |
GO:190129314 | Prostate | Tumor | nucleoside phosphate biosynthetic process | 61/3246 | 256/18723 | 4.84e-03 | 2.37e-02 | 61 |
GO:000912612 | Prostate | Tumor | purine nucleoside monophosphate metabolic process | 15/3246 | 44/18723 | 5.49e-03 | 2.61e-02 | 15 |
GO:00091676 | Prostate | Tumor | purine ribonucleoside monophosphate metabolic process | 14/3246 | 41/18723 | 7.07e-03 | 3.18e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AMPD1 | SNV | Missense_Mutation | rs587779379 | c.826N>A | p.Asp276Asn | p.D276N | P23109 | protein_coding | deleterious(0.01) | probably_damaging(0.925) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | rs139512772 | c.202N>T | p.Arg68Cys | p.R68C | P23109 | protein_coding | deleterious(0) | possibly_damaging(0.836) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | novel | c.49C>A | p.Leu17Ile | p.L17I | P23109 | protein_coding | tolerated_low_confidence(0.27) | benign(0.003) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | novel | c.1064N>A | p.Ser355Tyr | p.S355Y | P23109 | protein_coding | deleterious(0.01) | possibly_damaging(0.857) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | novel | c.347N>C | p.Asn116Thr | p.N116T | P23109 | protein_coding | tolerated(0.13) | benign(0) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | rs374697989 | c.2140G>A | p.Glu714Lys | p.E714K | P23109 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
AMPD1 | SNV | Missense_Mutation | | c.1107N>T | p.Glu369Asp | p.E369D | P23109 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | | c.976N>A | p.Asp326Asn | p.D326N | P23109 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | rs368656142 | c.599N>A | p.Arg200Gln | p.R200Q | P23109 | protein_coding | tolerated(0.21) | possibly_damaging(0.844) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | | c.2152A>G | p.Asn718Asp | p.N718D | P23109 | protein_coding | deleterious(0) | possibly_damaging(0.877) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |